We also confirmed amplification and concomitant overexpression of CCND1 as a recurrent alteration in PC [8], suggesting that a subset of PC depends on the deregulation of this druggable pathway and, in one case, triggering the recommendation of a CDK4/6 inhibitor. This evidence concerns the gene CDK4 and pachyonychia congenita.